Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherPROSTAGLANDINS, LEUKOTRIENES AND OTHER EICOSANOIDS

Potencies of Leflunomide and HR325 as Inhibitors of Prostaglandin Endoperoxide H Synthase-1 and -2: Comparison with Nonsteroidal Anti-Inflammatory Drugs

Adam P. Curnock, Peter A. Robson, Christopher M. Yea, David Moss, Suresh Gadher, T. Andrew Thomson, Robert Westwood, Erik Ruuth and Richard A. Williamson
Journal of Pharmacology and Experimental Therapeutics July 1997, 282 (1) 339-347;
Adam P. Curnock
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter A. Robson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher M. Yea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Moss
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suresh Gadher
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. Andrew Thomson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Westwood
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erik Ruuth
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard A. Williamson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The relative anti-inflammatory activities of the immunomodulators HR325 and leflunomide, or its active metabolite A77 1726, were examined by determining potencies in vitro on prostaglandin endoperoxide H synthase (PGHS) and in vivo in rat air pouch inflammation. Nonsteroidal anti-inflammatory drugs (NSAIDs) were used as comparators. HR325 was more potent than A77 1726 as an inhibitor of PGHS in guinea pig polymorphonuclear leukocytes (IC50 = 415 and 4400 nM, respectively) and on isolated ovine PGHS-1 (IC50 = 64 and 742 μM) and PGHS-2 (IC50 = 100 and 2766 μM). In vivo, in rat carrageenan air pouch inflammation, HR325 but not leflunomide at 25 mg/kg inhibited accumulation of leukocytes (48%) and PGE2 (61%). HR325 was also more potent than A77 1726 against human peripheral blood mononuclear cell PGHS-1 [IC50 = 1.6 and 25.6 μM (thromboxane B2production) or 1.1 and 8 μM (PGE2 production)] and lipopolysaccharide-induced PGHS-2 in human adherent peripheral blood mononuclear cells (IC50 = 435 nM and 9.5 μM) and peripheral blood polymorphonuclear leukocytes (IC50 = 91 nM and 3.2 μM). HR325 had low PGHS-2 selectivity in the human (2.5–12-fold) and was a more potent PGHS-2 inhibitor than naproxen, ibuprofen and piroxicam (2–8-fold). Assays using endogenous arachidonic acid as substrate yielded IC50 values for NSAIDs that were in general markedly lower than those published for assays using 10 μM substrate. With this approach, piroxicam had reasonable activity on human PGHS-2 (IC50 = 260–290 nM). Only NS398 and flufenamic acid were PGHS-2 selective in the human (90–330-fold and 37–60-fold, respectively); the other NSAIDs were either PGHS-1-selective (naproxen, ibuprofen, flurbiprofen and indomethacin) or nonselective (piroxicam and diclofenac). Inclusion of 10% human plasma reduced HR325 potency against PGHS-1 in human peripheral blood mononuclear cells approximately 32-fold (IC50 = 36 μM). Plasma protein binding further reduced HR325 potency (IC50 = 164 μM) and minimized the difference between HR325 and A77 1726 (IC50 = 292 μM) in a whole blood PGHS assay. Whether the greater activity against human PGHS-2 would allow HR325 to exhibit NSAID-like therapeutic effects in humans remains unclear.

Footnotes

  • Send reprint requests to: E. Ruuth, Domaine Therapeutic Immunology, Roussel UCLAF, 102/111 Route de Noisy, Romainville, France.

  • ↵1 Present address: Ferring Research Institute, Chilworth Research Centre, Southampton, SO16 7NP, UK.

  • ↵2 Present address: Enzyme Pharmacology Unit, Glaxo Wellcome, Medicines Research Centre, Gunnels Wood Road, Stevenage, Herts, SG1 2NY, UK.

  • Abbreviations:
    DMSO
    dimethylsulfoxide
    DTH
    delayed-type hypersensitivity
    HHT
    12-hydroxyheptadecatrienoic acid
    HPTLC
    high-performance thin-layer chromatography
    LPS
    lipopolysaccharide
    NSAID
    nonsteroidal anti-inflammatory drug
    PBMC
    peripheral blood mononuclear cell
    PBS
    phosphate-buffered saline
    PGHS
    prostaglandin endoperoxide H synthase
    PMNL
    polymorphonuclear leukocyte
    RIA
    radioimmunoassay
    TXB2
    thromboxane B2
    SDS-PAGE
    sodium dodecyl sulphate-poly acrylamide gel electrophoresis
    • Received September 24, 1996.
    • Accepted February 26, 1997.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 282, Issue 1
1 Jul 1997
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Potencies of Leflunomide and HR325 as Inhibitors of Prostaglandin Endoperoxide H Synthase-1 and -2: Comparison with Nonsteroidal Anti-Inflammatory Drugs
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherPROSTAGLANDINS, LEUKOTRIENES AND OTHER EICOSANOIDS

Potencies of Leflunomide and HR325 as Inhibitors of Prostaglandin Endoperoxide H Synthase-1 and -2: Comparison with Nonsteroidal Anti-Inflammatory Drugs

Adam P. Curnock, Peter A. Robson, Christopher M. Yea, David Moss, Suresh Gadher, T. Andrew Thomson, Robert Westwood, Erik Ruuth and Richard A. Williamson
Journal of Pharmacology and Experimental Therapeutics July 1, 1997, 282 (1) 339-347;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
OtherPROSTAGLANDINS, LEUKOTRIENES AND OTHER EICOSANOIDS

Potencies of Leflunomide and HR325 as Inhibitors of Prostaglandin Endoperoxide H Synthase-1 and -2: Comparison with Nonsteroidal Anti-Inflammatory Drugs

Adam P. Curnock, Peter A. Robson, Christopher M. Yea, David Moss, Suresh Gadher, T. Andrew Thomson, Robert Westwood, Erik Ruuth and Richard A. Williamson
Journal of Pharmacology and Experimental Therapeutics July 1, 1997, 282 (1) 339-347;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Biosynthesis of Sulfidopeptide Leukotrienes Via the Transfer of Leukotriene A4 from Polymorphonuclear Cells to Bovine Retinal Pericytes
  • The Preclinical Pharmacological Profile of the Potent and Selective Leukotriene B4 Antagonist CP-195543
  • NO-Independent Vasodilation to Acetylcholine in the Rat Isolated Kidney Utilizes a Charybdotoxin-Sensitive, Intermediate-Conductance Ca++-Activated K+ Channel
Show more PROSTAGLANDINS, LEUKOTRIENES AND OTHER EICOSANOIDS

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics